Efficacy and Safety of Levocetirizine Versus Loratadine for the Treatment of Perennial Allergic Rhinitis

Last updated: December 13, 2013
Sponsor: UCB Pharma
Overall Status: Completed

Phase

3

Condition

Nasal Obstruction

Common Cold

Rhinitis, Allergic, Perennial

Treatment

N/A

Clinical Study ID

NCT00524836
A00349
  • Ages 18-60
  • All Genders

Study Summary

Efficacy and Safety of Levocetirizine Versus Loratadine for the Treatment of Perennial Allergic Rhinitis.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Male ore female, 16 to 60 years old (inclusive)

  • two-year history of allergic rhinitis due to house dust mite

Exclusion

Exclusion Criteria:

  • An ear, nose or throat (ENT) infection

  • asthma requiring daily drug therapy other than ß2 inhaled agonists taken prn

  • atopic dermatitis or urticaria requiring an antihistamine or corticosteroid treatment

  • an associated ENT disease

  • use of decongestants

  • nasal or ocular topical treatment

  • desensitivation

Study Design

Total Participants: 71
Study Start date:
September 01, 2003
Estimated Completion Date:
February 29, 2004